Clinical Trial Update: Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing whether deep multi-omics profiling can predict response, resistance and recurrence to adjuvant atezolizumab plus bevacizumab in patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING